Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are beco...

Full description

Bibliographic Details
Main Authors: Luigi Principe, Tommaso Lupia, Lilia Andriani, Floriana Campanile, Davide Carcione, Silvia Corcione, Francesco Giuseppe De Rosa, Roberto Luzzati, Giacomo Stroffolini, Marina Steyde, Giuliana Decorti, Stefano Di Bella
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceuticals
Subjects:
β-lactams
β-lactamase inhibitors
cefiderocol
pharmacokinetics
pharmacodynamics
Online Access:https://www.mdpi.com/1424-8247/15/4/463

Internet

https://www.mdpi.com/1424-8247/15/4/463

Similar Items